Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arrowhead Pharma Q3 EPS $(1.26) Misses $(0.89) Estimate, Sales $27.767M Beat $23.711M Estimate

Author: Benzinga Newsdesk | August 07, 2025 03:04pm
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.89) by 41.57 percent. This is a 8.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $27.767 million which beat the analyst consensus estimate of $23.711 million by 17.11 percent.

Posted In: ARWR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist